Sign in

    Matthew Hershenhorn

    FINRA-registered representative at Oppenheimer & Co. Inc.

    Matthew Hershenhorn is an Equity Research Associate and Analyst at Oppenheimer & Co. Inc., specializing in coverage of high-growth biotech companies such as Axsome Therapeutics and Viking Therapeutics. With a demonstrated ability to identify promising pharmaceutical pipelines, he has delivered impactful calls such as maintaining a Buy rating and setting ambitious price targets on Axsome, which has outperformed the broader market by a notable margin. Hershenhorn holds a Chartered Financial Analyst designation and has worked in the securities industry since at least 2019, establishing credibility through his in-depth financial analysis and investment strategies. He is a FINRA-registered representative at Oppenheimer & Co. Inc., adding recognized regulatory credentials to his professional profile.

    Matthew Hershenhorn's questions to Skye Bioscience (SKYE) leadership

    Matthew Hershenhorn's questions to Skye Bioscience (SKYE) leadership • Q2 2025

    Question

    Matthew Hershenhorn of Oppenheimer & Co. Inc. asked about weight loss efficacy expectations for the CBEYOND trial, key secondary metrics, potential discontinuation rates, and the eligibility criteria for the extension study.

    Answer

    President, CEO & Director Punit Dhillon stated the Phase 2a trial is a proof-of-mechanism study, where a 5-8% placebo-adjusted weight loss would be a strong signal. He emphasized the goal is to validate the mechanism and establish a strong safety profile. Chief Medical Officer Dr. Puneet Arora clarified that approximately 50% of patients are eligible for the extension study primarily due to the logistical timing of its setup, not just patient dropouts.

    Ask Fintool Equity Research AI

    Matthew Hershenhorn's questions to Axsome Therapeutics (AXSM) leadership

    Matthew Hershenhorn's questions to Axsome Therapeutics (AXSM) leadership • Q2 2025

    Question

    Matthew Hershenhorn asked how Axsome plans to leverage its Sunosi commercial team for the AXS-12 launch and about its overall strategy in narcolepsy with two products.

    Answer

    Chief Commercial Officer Ari Maizel highlighted the 'near perfect overlap' in physician targets, allowing the Sunosi team to be fully leveraged for AXS-12, creating a 'real synergistic opportunity.' He noted that polypharmacy is common, and with distinct indications, he could foresee combination use of the two products.

    Ask Fintool Equity Research AI